FDA Brief

Warning letters Drugs

FDA warning letter to

RonanRx, Inc. dba RonanRx

LowIssued Oct 30Posted Nov 3Center for Drug Evaluation and Research (CDER)

FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

What happened

FDA reviewed RonanRx's website (ronanrx.com) and its social media platforms, including the X account @Ronan_Rx, in September 2026. FDA found the site and posts suggested the compounded semaglutide and tirzepatide products were FDA-approved, showed labels naming RonanRx as the maker even though it does not compound them, and called the drugs "American made" and "farm-to-table" although FDA records show no U.S.-registered maker of the active ingredients. FDA calls these products misbranded (misbranded means the labeling or advertising is false or misleading).

What FDA found

  1. Photos of compounded tirzepatide on the website and X show a label reading "RonanRx," implying RonanRx made the drug when it did not.

    FD&C Act section 502(a) [21 U.S.C. § 352(a)]
  2. The website calls the products "Well-Studied Compounded Medications" and "FDA-Approved Compounded Medications," implying FDA approval that compounded drugs do not have.

    FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. The X bio "Explore GLP-1s like Ozempic" and a pinned video saying "seventy-eight dollars a month, for drugs like Ozempic" link the compounded drugs to an approved brand drug in a misleading way.

    FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  4. A video calls the drugs "American made" and "farm-to-table drugs" with American flag imagery, though FDA records show the active ingredient was not made in the U.S.

    FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  5. Selling or shipping these misbranded drugs across state lines is a prohibited act.

    FD&C Act section 301(a) [21 U.S.C. § 331(a)]
  6. Compounded drugs must meet the conditions of section 503A or 503B (the rules that let compounders avoid standard new drug approval) to be legally marketed.

    FD&C Act sections 503A and 503B [21 U.S.C. §§ 353a, 353b]

What FDA wants

FDA tells RonanRx to reply in writing to the Office of Compounding Quality and Compliance within 15 working days, describing steps taken to fix the violations and prevent repeat ones. The reply should identify the entities that make the compounded products, include sample labeling, and show the misleading website and social media claims have been removed or corrected.

Who should pay attention

  • telehealth and online sellers marketing compounded GLP-1 drugs
  • compounders whose products are promoted by outside marketers
  • companies making U.S.-origin or FDA-approval claims in ads

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stokes Healthcare Inc. dba Epicur Pharma

    FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.

    High risk
  2. Amie Health, Inc. dba Amie

    FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  3. Maximus Health, Inc. dba Maximus

    FDA warned Maximus Health that its website makes false or misleading claims about compounded semaglutide and tirzepatide.

    Low
  4. Zeuss LLC dba Zeuss

    FDA warned telehealth seller Zeuss that its website misbrands compounded tirzepatide by implying Zeuss makes it and that it is FDA-approved.

    Medium